Thera-SAbDab

CEMIPLIMAB

> Structural Summary

Therapeutic	Cemiplimab
Target	PDCD1
Heavy Chain	EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS
Light Chain	DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G4
Highest Clinical Trial (June '19)	Approved
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2018
INN Year Recommended	2019
Companies Involved	Inovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sidney Kimmel Cancer Center, SillaJen Biotherapeutics, University of Texas M. D. Anderson Cancer Center
Conditions Approved	Squamous cell cancer
Conditions Active	Cervical cancer, Non-small cell lung cancer, Basal cell cancer, Oropharyngeal cancer, Prostate cancer, Fallopian tube cancer, Glioblastoma, Multiple myeloma, Ovarian cancer, Peritoneal cancer, Solid tumours, B-cell lymphoma, Cancer, Head and neck cancer, Malignant melanoma, Renal cell carcinoma
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]